Patent ID: 11890297
Assignee: BRII BIOSCIENCES, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating or preventing an HIV infection, comprising administering to a subject in need thereof an effective amount of:
(a) a capsid inhibitor; and
(b) an adenosine derivative, wherein the adenosine derivative is a compound of formula (1):, , or a pharmaceutically acceptable salt thereof,, wherein:
R1 is H, -L1-R5, or —Z-L4-R5;
R1′ is H or -L1-R5;
R2 is H or —R5, provided that least one of R1 and R2 is not H;
R5 is:, R6 is H, C1-C10 alkyl, C2-C10 alkenyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, aryl, or heteroaryl;
-L1-R5 is —(C1-C10 alkylene)-N(R7)—R5, —(C1-C10 alkylene)-O—R5, —(C1-C10 alkylene)-S—R5, —(C2-C10 alkenylene)-N(R7)—R5, —(C2-C10 alkenylene)-O—R5, —(C2-C10 alkenylene)-S—R5, —C(O)O—R5, —C(O)O-L2-N(R7)—R5, —C(O)O-L2-O—R5, —C(O)O-L2-S—R5, —C(O)O-L2-C(O)O—R5, —C(O)O-L2-C(O)N(R7)—R5, —C(O)O-L2-C(O)N(R7)-L3-N(R7)—R5, —C(O)O-L2-C(O)N(R7)-L3-O—R5, —C(O)O-L2-C(O)N(R7)-L3-S—R5, —C(O)N(R7)—R5, —C(O)N(R7)-L2-N(R7)—R5, —C(O)N(R7)-L2-O—R5, —C(O)N(R7)-L2-S—R5, —C(O)N(R7)-L2-C(O)O—R5, —C(O)N(R7)-L2-C(O)N(R8)—R5—, —C(O)N(R7)-L2-C(O)N(R8)-L3-N(R7)—R5, —C(O)O-L2-N(R7)C(O)O—R5, —C(O)N(R8)-L2-N(R7)C(O)O—R5, —C(O)O-L2-N(R7)C(O)N(R8)—R5, —C(O)N(R7)-L2-N(R7)C(O)N(R8)—R5, —C(O)N(R7)-L2-C(O)N(R8)-L3-O—R5 or —C(O)N(R7)-L2-C(O)N(R8)-L3-S—R5;
—Z— is —C(O)—, —C(O)O—, or —C(O)N(R7)—;
-L4-R5 is —(C1-C10 alkylene)-N(R7)—R5, —(C1-C10 alkylene)-O—R5, —(C1-C10 alkylene)-S—R5, —(C2-C10 alkenylene)-N(R7)—R5, —(C2-C10 alkenylene)-O—R5, —(C2-C10 alkenylene)-S—R5 or —(C3 alkylene)-N(R7)—C(O)—R5;
R7 and R8 each is independently H, C1-C10 alkyl, or C2-C10 alkenyl;
R9 is independently H, —F, C1-C10 alkyl, or C2-C10 alkenyl;
L2 and L3 each is divalent —(C1-C10 alkylene)- or —(C2-C10 alkenylene)-; and
X is a halogen atom.